The Role of Genetics in Risk Stratification Strategy of Dilated Cardiomyopathy

Dilated cardiomyopathy (DCM) is a heart disorder of diverse etiologies that affects millions of people worldwide, associated with increased mortality rate and high risk of sudden cardiac death. Patients with DCM are characterized by a wide range of clinical and pre-clinical phenotypes which are rela...

Full description

Saved in:
Bibliographic Details
Published in:Reviews in cardiovascular medicine 2022-09, Vol.23 (9), p.305
Main Authors: Xintarakou, Anastasia, Kariki, Ourania, Doundoulakis, Ioannis, Arsenos, Petros, Soulaidopoulos, Stergios, Laina, Aggeliki, Xydis, Panagiotis, Kordalis, Athanasios, Nakas, Nikolaos, Theofilou, Alexia, Vlachopoulos, Charalampos, Tsioufis, Konstantinos, Gatzoulis, Konstantinos A
Format: Article
Language:English
Subjects:
dilated cardiomyopathy
genetic testing
prevention
Review
risk stratification
sudden cardiac death
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dilated cardiomyopathy (DCM) is a heart disorder of diverse etiologies that affects millions of people worldwide, associated with increased mortality rate and high risk of sudden cardiac death. Patients with DCM are characterized by a wide range of clinical and pre-clinical phenotypes which are related with different outcomes. Dominant studies have failed to demonstrate the value of the left ventricular ejection fraction as the only indicator for patients' assessment and arrhythmic events prediction, thus making sudden cardiac death (SCD) risk stratification strategy improvement, more crucial than ever. The multifactorial two-step approach, examining non-invasive and invasive risk factors, represents an alternative process that enhances the accurate diagnosis and the individualization of patients' management. The role of genetic testing, regarding diagnosis and decision making, is of great importance, as pathogenic variants have been detected in several patients either they had a disease relative family history or not. At the same time there are specific genes mutations that have been associated with the prognosis of the disease. The aim of this review is to summarize the latest data regarding the genetic substrate of DCM and the value of genetic testing in patients' assessment and arrhythmic risk evaluation. Undoubtedly, the appropriate application of genetic testing and the thoughtful analysis of the results will contribute to the identification of patients who will receive major benefit from an implantable defibrillator as preventive treatment of SCD.
ISSN:1530-6550
2153-8174
1530-6550
DOI:10.31083/j.rcm2309305